Cytovia.png
Olivier Gouédard, PharmD, MBA joins Cytovia Therapeutics as Chief Operating Officer
June 22, 2021 08:55 ET | Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., June 22, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...
Cytovia.png
William Sullivan, CPA, MBA joins Cytovia Therapeutics as Chief Financial Officer
June 15, 2021 13:21 ET | Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., June 15, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...
Cytovia.png
Cytovia Therapeutics Expands Leadership Team
May 13, 2021 09:48 ET | Cytovia Therapeutics
Jason Aryeh elected to Board of DirectorsElizabeth Schwarzbach, PhD and Boris Reznik, PhD join Strategic Advisory BoardElysa Mantel appointed as Vice President, General Counsel and Corporate Secretary...
Cytovia.png
Stanley R. Frankel, MD, FACP joins Cytovia Therapeutics as Chief Medical Officer
April 28, 2021 13:16 ET | Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., April 28, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...
Cytovia.png
Cytovia Therapeutics Files New Patents for its Natural Killer Cell Engager Multifunctional Antibodies (FLEX-NK®) for the Treatment of Hematological and Solid Tumors
April 12, 2021 11:11 ET | Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., April 12, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...